As AbbVie continues to capitalize on its ImmunoGen deal, the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FDA finish ...

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. Sarchi joins Bicara after a ...

The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...

Brain cancers are notoriously difficult to treat, with surgery and radiation continuing to be the main options for these malignancies. A rare and aggressive type of brain tumor driven by a particular ...

Johnson & Johnson (JNJ) reported new clinical trial results showing that its experimental subcutaneous formulation of amivantamab produced durable responses in patients with advanced head and neck ...

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

OS Therapies signed agreements for the commercial manufacture of OST-HER2 as it prepares for an FDA meeting and potential BLA submission. Phase 2b data show OST-HER2 significantly improved 12-month ...